```html

Transverse Myelitis – Comprehensive Medical Guide

Overview

Transverse myelitis (TM) is an inflammatory disorder of the spinal cord that damages or destroys myelin—the protective covering of nerve fibers. The inflammation typically occurs across one level of the spinal cord (hence “transverse”), leading to a sudden onset of neurologic deficits that can affect motor, sensory, and autonomic functions.

• Who it affects: TM can occur at any age, but it most commonly appears in young adults (20‑40 years) and in children aged 5‑15 years.
• Prevalence: In the United States, the incidence is estimated at 1‑4 cases per million people per year, with a lifetime prevalence of roughly 3‑5 per 100,000. It is slightly more common in females (≈55 %).
• Key point: While most cases are isolated (single episode), up to 15‑20 % progress to chronic demyelinating diseases such as multiple sclerosis or neuromyelitis optica spectrum disorder (NMOSD).

Symptoms

The clinical picture varies depending on the level of the spine involved (cervical, thoracic, lumbar) and the extent of inflammation. Symptoms typically develop over hours to days.

Motor symptoms

• Weakness or paralysis: May be mild (grade 4/5) to severe (paraplegia or quadriplegia) on the side of the body below the lesion.
• Spasticity: Increased muscle tone and reflexes, often worsening over weeks.
• Loss of coordination: Difficulty with fine motor tasks and walking.

Sensory symptoms

• Pain: Burning, stabbing, or “electric shock” sensations. Pain is common (≈70 % of patients) and may precede motor deficits.
• Numbness or tingling: A “pins‑and‑needles” feeling that follows a dermatomal pattern.
• Loss of vibration/position sense: Contributes to gait instability.

Autonomic (bodily) symptoms

• Bladder dysfunction: Urinary urgency, frequency, or retention.
• Bowel dysfunction: Constipation or loss of control.
• Sexual dysfunction: Erectile dysfunction in men; decreased lubrication in women.
• Thermoregulation issues: Sweating abnormalities and temperature intolerance.

Systemic symptoms (often precede neurologic signs)

• Fever, chills, or recent viral illness (up to 45 % report a preceding infection).
• Headache, neck stiffness, or malaise.

Causes and Risk Factors

Transverse myelitis is not a single disease but a syndrome with many possible triggers.

Infectious triggers

• Viral: Enterovirus, West Nile, Herpes simplex, Varicella‑zoster, Influenza, COVID‑19 (SARS‑CoV‑2).
• Bacterial: Mycoplasma pneumoniae, Borrelia burgdorferi (Lyme disease), Treponema pallidum.
• Parasitic: Rarely Schistosoma species.

Immune‑mediated disorders

• Multiple sclerosis (MS) – TM may be the first manifestation.
• Neuromyelitis optica spectrum disorder (NMOSD) – often associated with anti‑AQP4 antibodies.
• Systemic autoimmune diseases: Lupus, Sjögren’s syndrome, Sarcoidosis, Behçet’s disease.

Post‑vaccination or post‑procedural

• Rare reports after influenza, tetanus, hepatitis B, and COVID‑19 vaccines. The overall risk remains extremely low (≈1 case per million doses).

Other risk factors

• Recent infection or vaccination (within 30 days).
• Age < 30 or > 50 (bimodal distribution).
• Female sex (slightly higher prevalence).
• Genetic predisposition to autoimmune disease.

Diagnosis

Because TM mimics many neurologic conditions, a systematic approach is essential.

Clinical assessment

• Detailed history (onset, preceding illness, vaccination, trauma).
• Neurologic examination to localize the lesion (determining the “sensory level”).

Imaging studies

• MRI of the spine (with and without contrast): Gold standard. Shows T2 hyperintensity spanning ≥ 1 vertebral segment, often with gadolinium enhancement indicating active inflammation.
• Brain MRI: Helps rule out MS or NMOSD lesions.

Laboratory tests

• Blood work: CBC, ESR, CRP, ANA, anti‑AQP4, anti‑MOG antibodies, viral serologies, Lyme titers.
• CSF analysis (lumbar puncture): Elevated protein, pleocytosis (lymphocytic predominance), oligoclonal bands (in ~30 % of cases), and exclusion of infection (PCR for HSV, VZV, CMV, SARS‑CoV‑2, etc.).

Other tests

• Evoked potentials (visual, somatosensory) – assess subclinical demyelination.
• Urodynamic studies – baseline bladder function.

Treatment Options

Early intervention improves neurologic recovery. Treatment usually combines high‑dose steroids, plasma exchange, and supportive care.

Acute pharmacologic therapy

• Corticosteroids: Intravenous methylprednisolone 1 g daily for 3‑5 days (or 500 mg if weight‑based dosing). Followed by an oral taper over 4‑6 weeks to limit rebound inflammation.
• Plasma exchange (PLEX): Considered if no improvement after steroids, or if severe deficits are present. Typical regimen: 5‑7 exchanges every other day.
• Intravenous immunoglobulin (IVIG): Alternative when PLEX unavailable; dose 0.4 g/kg/day for 5 days.
• Targeted therapies for NMOSD: Anti‑AQP4 antibodies respond to eculizumab, satralizumab, or inebilizumab.

Symptom‑focused medications

• Analgesics: Gabapentin or pregabalin for neuropathic pain; NSAIDs for musculoskeletal discomfort.
• Antispasmodics: Baclofen or tizanidine for spasticity.
• Bladder agents: Anticholinergics (oxybutynin) or intermittent catheterization.

Rehabilitation and supportive procedures

• Physical therapy – gait training, strengthening, balance work.
• Occupational therapy – adaptive equipment, ADL (activities of daily living) training.
• Speech‑language therapy – if high cervical lesions affect swallowing.
• Psychological support – counseling for depression/anxiety.

Lifestyle and home measures

• Maintain a balanced diet rich in omega‑3 fatty acids and antioxidants to support neural health.
• Stay hydrated; bladder programs to reduce urinary tract infection risk.
• Avoid smoking – it worsens vascular and inflammatory processes.

Living with Transverse Myelitis

Daily management tips

• Mobility: Use braces or walkers as prescribed; maintain regular stretching to prevent contractures.
• Pain control: Keep a pain diary, adjust medications in consultation with your neurologist.
• Bladder care: Scheduled voiding, pelvic floor exercises, and clean intermittent catheterization if needed.
• Skin integrity: Inspect pressure areas daily; use cushions for wheelchair users.
• Exercise: Low‑impact activities (swimming, stationary bike) improve circulation and mental health.
• Vaccinations: Stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines—these reduce infection‑related relapses.

Psychosocial considerations

• Join support groups (e.g., TM Association, MS societies) for peer encouragement.
• Consider vocational rehab if work capabilities change.
• Family education – ensure caregivers understand safe transfers and emergency signs.

Prevention

Because many cases are triggered by infections or autoimmune activity, absolute prevention is not possible, but risk can be reduced.

• Practice good hand hygiene and avoid close contact with individuals who have active viral illnesses.
• Stay current on recommended vaccinations; the benefits outweigh the tiny risk of post‑vaccination TM.
• Promptly treat infections, especially respiratory or urinary tract infections, to limit systemic inflammation.
• Manage chronic autoimmune diseases (e.g., lupus) under specialist care to keep systemic inflammation low.

Complications

If left untreated or inadequately managed, TM can lead to long‑term disability.

• Permanent motor deficits: Persistent weakness or paralysis.
• Chronic neuropathic pain: May become refractory to standard analgesics.
• Severe spasticity: Can cause contractures, pressure ulcers, and joint degeneration.
• Neurogenic bladder: Recurrent urinary tract infections, renal damage.
• Autonomic dysreflexia: Dangerous hypertensive spikes, especially with high‑level lesions.
• Progression to demyelinating disease: Up to 20 % develop MS or NMOSD, requiring long‑term disease‑modifying therapy.

When to Seek Emergency Care

References

• Mayo Clinic. “Transverse Myelitis.” https://www.mayoclinic.org
• National Institute of Neurological Disorders and Stroke (NINDS). “Transverse Myelitis Information Page.” https://www.ninds.nih.gov
• Cleveland Clinic. “Transverse Myelitis.” https://my.clevelandclinic.org
• World Health Organization. “Neurological Disorders: Overview.” https://www.who.int
• J. A. Kantarci et al., “Long‑term Outcomes in Transverse Myelitis,” *Neurology*, 2022.
• CDC. “Vaccine Safety and Adverse Events.” https://www.cdc.gov

```